These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29930748)

  • 1. Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases.
    Loosen SH; Tacke F; Binnebosel M; Leyh C; Vucur M; Heitkamp F; Schoening W; Ulmer TF; Alizai PH; Trautwein C; Koch A; Longerich T; Roderburg C; Neumann UP; Luedde T
    Oncotarget; 2018 Jun; 9(43):27027-27038. PubMed ID: 29930748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.
    Loosen SH; Breuer A; Tacke F; Kather JN; Gorgulho J; Alizai PH; Bednarsch J; Roeth AA; Lurje G; Schmitz SM; Brozat JF; Paffenholz P; Vucur M; Ritz T; Koch A; Trautwein C; Ulmer TF; Roderburg C; Longerich T; Neumann UP; Luedde T
    JHEP Rep; 2020 Apr; 2(2):100080. PubMed ID: 32140677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma.
    Loosen SH; Tacke F; Püthe N; Binneboesel M; Wiltberger G; Alizai PH; Kather JN; Paffenholz P; Ritz T; Koch A; Bergmann F; Trautwein C; Longerich T; Roderburg C; Neumann UP; Luedde T
    Carcinogenesis; 2019 Aug; 40(8):947-955. PubMed ID: 30805627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Levels of Osteopontin Predict Patients' Outcome after Resection of Colorectal Liver Metastases.
    Loosen SH; Heise D; Dejong CH; Roy S; Tacke F; Trautwein C; Roderburg C; Luedde T; Neumann UP; Binnebösel M
    J Clin Med; 2018 Oct; 7(11):. PubMed ID: 30373147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated soluble urokinase plasminogen activator receptor serum levels indicate poor survival following transarterial chemoembolization therapy for hepatic malignancies: An exploratory analysis.
    Loosen SH; Schulze-Hagen M; Vucur M; Gorgulho J; Paffenholz P; Benz F; Mohr R; Demir M; Wree A; Kuhl C; Trautwein C; Tacke F; Bruners P; Luedde T; Roderburg C
    JGH Open; 2021 Mar; 5(3):356-363. PubMed ID: 33732882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Analysis of Circulating Biomarkers for Patients Undergoing Resection of Colorectal Liver Metastases.
    Loosen SH; Roderburg C; Alizai PH; Roeth AA; Schmitz SM; Vucur M; Luedde M; Schöler D; Paffenholz P; Tacke F; Trautwein C; Luedde T; Neumann UP; Ulmer TF
    Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Predictive Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention.
    Qin Y; Qiao Y; Wang D; Yan G; Tang C; Ma G
    Int J Gen Med; 2021; 14():6497-6504. PubMed ID: 34675617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
    Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
    Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.
    Loosen SH; Gorgulho J; Jördens MS; Schulze-Hagen M; Beier F; Vucur M; Schneider AT; Koppe C; Mertens A; Kather JN; Tacke F; Keitel V; Brümmendorf TH; Roderburg C; Luedde T
    Front Oncol; 2021; 11():646883. PubMed ID: 33869041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated Soluble Urokinase Plasminogen Activator Receptor and Proenkephalin Serum Levels Predict the Development of Acute Kidney Injury after Cardiac Surgery.
    Mossanen JC; Pracht J; Jansen TU; Buendgens L; Stoppe C; Goetzenich A; Struck J; Autschbach R; Marx G; Tacke F
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure.
    Koch A; Zimmermann HW; Gassler N; Jochum C; Weiskirchen R; Bruensing J; Buendgens L; Dückers H; Bruns T; Gerken G; Neumann UP; Adams DH; Trautwein C; Canbay A; Tacke F
    Liver Int; 2014 Oct; 34(9):1330-9. PubMed ID: 24575897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
    Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
    Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
    Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
    Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor levels predict survival in patients with portal hypertension undergoing TIPS.
    Loosen SH; Benz F; Mohr R; Reuken PA; Wirtz TH; Junker L; Jansen C; Meyer C; Praktiknjo M; Wree A; Reißing J; Demir M; Gu W; Vucur M; Schierwagen R; Stallmach A; Kunstein A; Bode J; Trautwein C; Tacke F; Luedde T; Bruns T; Trebicka J; Roderburg C
    JHEP Rep; 2024 May; 6(5):101054. PubMed ID: 38681861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
    Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
    Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.
    Sorio C; Mafficini A; Furlan F; Barbi S; Bonora A; Brocco G; Blasi F; Talamini G; Bassi C; Scarpa A
    BMC Cancer; 2011 Oct; 11():448. PubMed ID: 21999221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
    Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
    Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.